Bottom line
What does PBE hold?
PBE held 33 positions as of Jul 31, 2026. Its largest holding is Invesco Private Prime Fund at 12.89% of the fund, and the top 10 positions add up to 56.8%. By asset type it is 100% stocks, 18% cash & short-term funds.
Updated Sep 28, 2026
PBE top 25 holdings
| # | Holding | Type | % of fund | Value |
|---|---|---|---|---|
| 1 | Invesco Private Prime Fund | Cash & short-term funds | 12.89% | $36.3M |
| 2 | Regeneron Pharmaceuticals, Inc. | Stocks | 5.47% | $15.4M |
| 3 | Amgen Inc. | Stocks | 5.22% | $14.7M |
| 4 | CareDx, Inc. | Stocks | 5.04% | $14.2M |
| 5 | Vertex Pharmaceuticals Inc. | Stocks | 4.99% | $14.1M |
| 6 | Invesco Private Government Fund | Cash & short-term funds | 4.97% | $14.0M |
| 7 | Royalty Pharma PLC Royalty Pharma PLC, Class A |
Stocks | 4.94% | $13.9M |
| 8 | Biogen Inc. | Stocks | 4.79% | $13.5M |
| 9 | Gilead Sciences, Inc. | Stocks | 4.43% | $12.5M |
| 10 | United Therapeutics Corp. | Stocks | 4.08% | $11.5M |
| 11 | Bio-Techne Corp. | Stocks | 3.73% | $10.5M |
| 12 | Illumina, Inc. | Stocks | 3.51% | $9.9M |
| 13 | Protagonist Therapeutics, Inc. | Stocks | 3.40% | $9.6M |
| 14 | Vericel Corp. | Stocks | 3.27% | $9.2M |
| 15 | Alnylam Pharmaceuticals, Inc. | Stocks | 3.17% | $8.9M |
| 16 | Incyte Corp. | Stocks | 3.06% | $8.6M |
| 17 | Repligen Corp. | Stocks | 3.04% | $8.6M |
| 18 | Acadia Pharmaceuticals Inc. | Stocks | 3.02% | $8.5M |
| 19 | Halozyme Therapeutics, Inc. | Stocks | 2.98% | $8.4M |
| 20 | Qiagen N.V. | Stocks | 2.89% | $8.2M |
| 21 | BioMarin Pharmaceutical Inc. | Stocks | 2.82% | $8.0M |
| 22 | Neurocrine Biosciences, Inc. | Stocks | 2.66% | $7.5M |
| 23 | Exelixis, Inc. | Stocks | 2.64% | $7.4M |
| 24 | BioCryst Pharmaceuticals, Inc. | Stocks | 2.63% | $7.4M |
| 25 | Veracyte, Inc. | Stocks | 2.60% | $7.3M |
Source: SEC Form N-PORT, period ended Jul 31, 2026, filed Sep 28, 2026